Early Immune System Development and Ontogeny (R01 Clinical Trial Optional)
View on Grants.gov ↗ Sign in to save
- Type
- Grant
- Notice type
- G
- Agency
- National Institutes of Health
- Sub-agency
- HHS-NIH11
- Solicitation #
- PAR-25-362
- Posted
- Dec 30, 2024
- Response due
- Nov 5, 2028
- Archive date
- Dec 5, 2028
- CFDA / Assistance listing
- 93.865
- Award ceiling
- $400,000
- Contact
- grantsinfo@nih.gov
- Source
- Grants.gov
Description
The purpose of this Notice of Funding Opportunity (NOFO) is tofurther elucidate the mechanisms of early immune development in utero, during the early post-natal period and during early childhood in neonates, infants, and children and adolescents with or without in-utero exposure to HIV or Anti-Retroviral Therapeutics (ART).This initiative aims to understand intricate mechanisms of immune cells at the maternal-fetal interface, T and B cell development and maturation in offspring, and local immune responses and the role of systemic immunity.